

1st Cuneo City Immunotherapy Conference (CCITC)

Immunotherapy in Hematological Malignancies 2018

CUNEO May 17-19, 2018 Centro Incontri

PDI/PDL1 blockade in Hodgkin lymphoma (Armando Santoro - Rozzano - MI)

Organized by Prof. Massimo Massaia, SC Ematologia AO S. Croce e Carle, Cuneo, Italy and Centro Interdipartimentale di Ricerca in Biologia Molecolare (CIRBM), Torino, Italy




CONFLITTO D'INTERESSI


- BMS
- ARQULE
- TAKEDA
- SERVIER
- BAYER
- ASTRA ZENECA

.....e altre

- GILEAD
- MSD
- ROCHE
- LILLY
- NOVARTIS
- SANDOZ











THE SUBSEQUENT STEPSKEYNOTE-087CHECKMATE-205





KEYNOTE-087 : PHASE 2 STUDY WITH PEMBROLIZUMAB IN R/R HL




ALL COHORTS (210 PTS)

Chen R, Zinzani PL, Fanale M, et al, JCO 2017



KEYNOTE-087: RESULTS BY COHORT



Chen R, Zinzani PL, Fanale M, et al, JCO 2017



KEYNOTE-087: SUBGROUP ANALYSIS

	Primary Refractory Disease (n = 73)		Relapsed After ≥3 Lines of Therapy (n = 146)	
	n (%)	n (%) 95% Cl [‡]		95% CI [‡]
ORR	58 (79.5)	68.4-88.0	99 (67.8)	59.6-75.3
Complete remission	17 (23.3)	14.2-34.6	31 (21.2)	14.9-28.8
Partial remission	41 (56.2)	44.1-67.8	68 (46.6)	38.3-55.0
Stable disease	4 (5.5)	1.5-13.4	24 (16.4)	10.8-23.5
Progressive disease	8 (11.0)	4.9-20.5	20 (13.7)	8.6-20.4
Unable to determine	3 (4.1)	0.9-11.5	3 (2.1)	0.4-5.9

⁺These subgroups are not mutually exclusive

*Based on binomial exact confidence interval method


Chen R, Zinzani PL, Fanale M, et al, JCO 2017



Checkmate 205: COHORT B NIVO IN ASCT+BV (60 PTS)

 OBJECTIVE RESPONSE: 66.3%,

 CR 9%,
 PR 58%



A. Younes, A. Santoro, M. Shipp et al, Lancet Oncol 2016




Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

Philippe Armand, Andreas Engert, Anas Younes, Michelle Fanale, Armando Santoro, Pier Luigi Zinzani, John M. Timmerman, Graham P. Collins, Radhakrishnan Ramchandren, Jonathon B. Cohen, Jan Paul De Boer, John Kuruvilla, Kerry J. Savage, Marek Trneny, Margaret A. Shipp, Kazunobu Kato, Anne Sumbul, Benedetto Farsaci, and Stephen M. Ansell

	BV naïve	BV after auto-HSCT	BV before and/or after auto-HSCT	Overall
	(Cohort A) n = 63	(Cohort B) n = 80	(Cohort C) n = 100	N = 243
Objective response per IRC, % (95% CI)	65 (52, 77)	68 (56, 78)	73 (63, 81)	69 (63, 75)
Best overall response per IRC, %				
Complete remission ^b	29	13	12	16
Partial remission	37	55	61	53
Stable disease	24	21	15	19
Progressive disease	11	8	10	9
Unable to determine	0	4	2	2



CHECKMATE 2015: MULTICOHORT RESULTS



Armand P, Engert A, Younes A, et al, JCO 2018




CHECKMATE 205: MULTICOHORT RESULTS ACCORDING TO DISEASE STATUS

	Refractory to first line	Refractory to last line	Refractory to BV after auto-HSCT
	(n = 142)	(n = 114)	(n = 70)
Objective response, %	73	68	69
Best overall response, % Complete remission Partial remission	18 55	13 54	6 63
Median DOR in patients with PR, months (95% CI)	13 (9, 18)	17 (9, NE)	17 (8, NE)ª

Armand P, Engert A, Younes A, et al, JCO 2018



PD1-BLOCKADE: SAFETY PROFILE






FDA APPROVAL OF CHECKPOINT INHIBITORS IN cHL


Agent	EU	US
Nivolumab	 Adult pts with relapsed/ refractory disease after ASCT and brentuximab vedotin Dosing: 3 mg/kg Q2W 	 Adult pts with relapsed/ progressed disease after ASCT and brentuximab vedotin Adult pts with relapsed/ progressed disease after ≥ 3 lines of systemic therapy including ASCT Dosing: 3 mg/kg Q2W
Pembroliz umab	 Adult pts with relapsed/ refractory disease after ASCT and brentuximab vedotin Adult pts with relapsed/ refractory disease who failed brentuximab vedotin and are transplantation 	 Adult or pediatric pts with refractory disease or who have relapsed after ≥ 3 previous lines of therapy Dosing: 200 mg Q3W (adults) or 2 mg/kg Q3W, up to 200

ITALIAN HL EAP WITH NIVOLUMAB




Santoro A et al ASH 2017

ITALIAN HL EAP WITH NIVOLUMAB



Santoro A et al ASH 2017







THE OPEN QUESTIONS



RESPONSE EVALUATION

THERAPY BEYOND PROGRESSION

ALLOTMO: YES OR NOT?

THERAPY DURATION

PREDICTORS OF RESPONSE



LYRIC CRITERIA

LYmphoma Response to Immunomodulatory therapy Criteria



IR	Definition
IR1	Increase in overall tumor burden (SD)≥50% of up to 6 measurable lesions in the first 12 ws of therapy without clinical deterioration
IR2	Appearance of new lesions, or growth of one or more existing lesions ≥50% at any time during treatment, occuring in the context of lack of overall progression of overall tumor burden
IR3	Increase in FDG uptake of one or more lesions without a concomitant increase in lesion size or number


Cheson B et al, Blood 2016




THE OPEN QUESTIONS: RESPONSE EVALUATION

Pt #270 - Baseline

Cycle 3




THE OPEN QUESTIONS: RESPONSE EVALUATION





THE OPEN QUESTIONS: WHEN TO STOP TREATMENT


CHECKMATE 205: NIVOLUMAB BEYOND PROGRESSION



Patients with investigator-assessed progression could continue to receive treatment until further progression (≥10% greater increase in tumor burden)



CHECKMATE 2015: NIVOLUMAB BEYOND PROGRESSION




Cohen JB et al, ASH 2017



WHEN TO STOP TREATMENT IN RESPONSIVE PATIENTS PROLONGED REMISSIONS AFTER ANTI-PD1 DISCONTINUATION

Figure 1. Outcome of patients after nivolumab discontinuation




Manson G et al, BLOOD 2018

Regular Article

TRANSPLANTATION

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma

Reid W. Merryman,¹ Haesook T. Kim,² Pier Luigi Zinzani,³ Carmelo Carlo-Stella,^{4,5} Stephen M. Ansell,⁶ Miguel-Angel Perales,⁷ Abraham Avigdor,⁸ Ahmad S. Halwani,⁹ Roch Houot,^{10,11} Tony Marchand,¹⁰ Nathalie Dhedin,¹² Willy Lescaut,¹³ Anne Thiebaut-Bertrand,¹⁴ Sylvie François,¹⁵ Aspasia Stamatoullas-Bastard,¹⁶ Pierre-Simon Rohrlich,¹⁷ Hélène Labussière Wallet,¹⁸ Luca Castagna,^{4,5} Armando Santoro,^{4,5} Veronika Bachanova,¹⁹ Scott C. Bresler,²⁰ Amitabh Srivastava,²⁰ Harim Kim,²¹ Emily Pesek,¹ Marie Chammas,¹ Carol Reynolds,¹ Vincent T. Ho,¹ Joseph H. Antin,¹ Jerome Ritz,¹ Robert J. Soiffer,¹ and Philippe Armand¹



CHECKPOINT INHIBITORS: TREATMENT DURATION



NO ALLO-TRANSPLANT

2 YEARS?

ALLO- TRANSPLANT

8 COURSES?



THE OPEN QUESTIONS: AFTER ALLO-TMO

CHECKPOINT INHIBITORS AFTER ALLO-TMO

EFFICACY AND TOLERABILITY OF NIVO AFTER ALLO-TMO FOR R-HL

HERBEAUX C ET AL , BLOOD 2017


PD-1 BLOCKADE FOR R-HL POST–ALLO-TMO: HIGH RESPONSE RATE BUT FREQUENT GVHD HAVERKOS BM ET AL, BLOOD 2017



HO IMPARATO COSI' TANTO DAI MIEI ERRORI CHE STO PENSANDO DI CONTINUARE A FARNE.




Expansion Phase Design



Evaluate for signs/symtpoms of GVHD: Patients who develop GVHD of any grade or treatment related Grade≥2 AEs with a duration of more than 14 days will NOT be dose escalated to 500 mg Q2W Patients with PD will be discontinued from the treatment











9p24.1 alterations



JCO 2018



KEYNOTE-087: PDL-1 SCORES and RESULTS



Chen R, Zinzani PL, Fanale M, et al, JCO 2017




THE NEXT SCENARIOS IN HL TREATMENT

HOW TO FIT CHECKPOINT INHIBITORS IN THE MANAGEMNET OF HL


NOVEL SALVAGE REGIMENS FOR R/R HL BEFORE ASCT

Salvage Regimen	Ν	ORR, %	CR by PET, %
BV + ICE (sequential)	37	86	65
BV + augICE (sequential)	45	82	76
BV + Bendamustine	55	93	74
BV + ESHAP (BRESHAP)	66	94	70
BV + ICE (concurrent)	16	94	69
BeGEV	59	83	73


THE NEXT SCENARIOS IN HL TREATMENT



THE NEXT SCENARIOS IN HL TREATMENT








- PATIENTS RECEIVED TREATMENT (TX) IN 21-DAY CYCLES FOR UP TO 4 CYCLES (12 WEEKS)
 - DURING CYCLE 1, BV WAS ADMINISTERED ON DAY 1 AND NIVO ON DAY 8
 - DURING CYCLES 2-4, DOSING OF BOTH DRUGS OCCURRED ON DAY 1
 - AFTER COMPLETION OF THE EOT RESPONSE ASSESSMENT, PATIENTS WERE ELIGIBLE TO UNDERGO ASCT
- RESPONSES WERE ASSESSED USING THE 2014 LUGANO CLASSIFICATION

Herrera AF, Moskowitz AJ, Bartlett NL, et al BLOOD 2018




85% OBJECTIVE RESPONSE RATE WITH 63% COMPLETE RESPONSES



	N = 61 %
COMPLETE RESPONSE (CR)	61
PARTIAL RESPONSE (PR)	21
NO METABOLIC RESPONSE (SD)	8
PROGRESSIVE DISEASE (PD)	8
CLINICAL PROGRESSION (CP)	2

Herrera AF, Moskowitz AJ, Bartlett NL, et al BLOOD 2018





Herrera AF, Moskowitz AJ, Bartlett NL, et al BLOOD 2018



ADVERSE EVENTS

98% of pts with AEs, most of which were low grade Grade 4 AEs only observed in 2 pts (3%; n = 1 thrombocytopenia, 1 increased lipase enzymes)

25 out of 27 IRRs occurred during BV infusion, most often during cycle 2 IRR severity and frequency not changed by pretreatment with lowdose steroid and antihistamine


AEs in > 20% of Pts, n (%)	Grade 1/2	Grade 3
Any	40 (66)	17 (28)
Nausea	30 (49)	0
Fatigue	24 (39)	1 (2)
IRRs	25 (41)	2 (3)
Pruritus	18 (30)	1 (2)
Diarrhea	15 (25)	1 (2)
Headache	15 (25)	0
Cough	13 (21)	0
Vomiting	13 (21)	0

BeGEV




Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study

Bendamustine 90 mg/mq d 2-3, Gemcitabine 800 mg/mq d 1-4, Vinorebine 20 mg/mq d 1



PHASE 1-2 STUDY WITH BeGEV PLUS PEMBROLIZUMAB

Bendamustine 90 mg/mq d 2-3, Gemcitabine 800 mg/mq d 1-4, Vinorebine 20 mg/mq d 1







- ✓ CHECKPOINT INHIBITORS CONFIRM:
 - HIGH ORR WITH LOW CR
 - TBP SHOULD BE CONSIDERED
 - ABSENCE OF PREDICTIVE TARGETS IN HL AFTER ASCT +/- BV
- ✓ STANDARD 2° LINE CT (BeGEV, ICE,..) FOLLOWED BY ASCT REMAIN THE GOLD STANDARD FOR R/R HL

✓ BY THE MOMENT NO DATA SUPPORT THE ADVANTAGE OF COMBINING CHECKPOINTS WITH BV OR CT VS STANDARD SALVAGE CT



